Hikma Pharmaceuticals (LON:HIK) had its price objective upped by Citigroup from GBX 2,100 ($27.44) to GBX 2,250 ($29.40) in a report issued on Wednesday, October 3rd. Citigroup currently has a buy rating on the stock.
A number of other equities analysts have also recently issued reports on HIK. Peel Hunt reissued a hold rating on shares of Hikma Pharmaceuticals in a report on Tuesday, July 3rd. Barclays reaffirmed an underweight rating on shares of Hikma Pharmaceuticals in a report on Tuesday, July 10th. Numis Securities cut Hikma Pharmaceuticals to a hold rating and set a GBX 1,560 ($20.38) price target on the stock. in a report on Thursday, August 9th. Finally, JPMorgan Chase & Co. reaffirmed a neutral rating and set a GBX 1,050 ($13.72) price target on shares of Hikma Pharmaceuticals in a report on Tuesday, August 21st. Two research analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of GBX 1,346.89 ($17.60).
LON:HIK opened at GBX 1,663 ($21.73) on Wednesday. Hikma Pharmaceuticals has a one year low of GBX 814.20 ($10.64) and a one year high of GBX 2,346 ($30.65).
The company also recently announced a dividend, which was paid on Friday, September 21st. Investors of record on Thursday, August 23rd were issued a dividend of $0.12 per share. The ex-dividend date of this dividend was Thursday, August 23rd. This represents a yield of 0.53%.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
See Also: Stop Order Uses For Individual Investors
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.